Karyopharm signals $130M-$150M revenue target for 2026 with pivotal myelofibrosis data readout ahead
Source: SeekingAlpha
2026-02-12 18:15:30 ET
More on Karyopharm Therapeutics
- Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call Transcript
- Karyopharm Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation
- Karyopharm Therapeutics GAAP EPS of -$5.71 misses by $3.67, revenue of $34.08M beats by $0.92M
- Seeking Alpha’s Quant Rating on Karyopharm Therapeutics
- Historical earnings data for Karyopharm Therapeutics
Read the full article on Seeking Alpha
For further details see:
Karyopharm signals $130M–$150M revenue target for 2026 with pivotal myelofibrosis data readout ahead
Karyopharm Therapeutics Inc.
NASDAQ: KPTI
KPTI Trading
-1.16% G/L:
$7.66 Last:
419,625 Volume:
$7.91 Open:
KPTI Latest News
February 12, 2026 07:30:00 am
Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
KPTI Stock Data
$121,122,522
16,512,213
2.62%
32
N/A
Biotechnology & Life Sciences
Healthcare
US
Newton
